Multidrug resistance phenotype and paclitaxel (Taxol®) sensitivity in human renal carcinoma cell lines of different histologic types

Cancer Investigation

Volumn 18, Issue 7, 2000, Pages 614-625

  Reinecke, Petra ^a   Schmitz, Michael ^a   Schneider, E Marion ^b   Gabbert, Helmut Erich ^a   Gerharz, Claus Dieter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROMINE DERIVATIVE; CREMOPHOR; DIMETHYL SULFOXIDE; GLYCOPROTEIN P; PACLITAXEL; VERAPAMIL;

ARTICLE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SENSITIVITY; ELECTRON MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033820308     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009032828     Document Type: Article

References (52)

1. Conservative surgery of renal cell tumors in 140 patients: 21 years of experience
2. Treatment of advanced renal cell carcinoma. Traditional methods and innovative approaches
3. Immunotherapy for metastatic renal cell carcinoma
4. Measurement of multidrug resistance messenger RNA in urogenital cancers: Elevated expression in renal cell carcinoma is associated with intrinsic drug resistance
5. Mechanism and modulation of multidrug resistance in primary human renal cell carcinoma
6. Taxol: The first of the Taxanes, an important new class of antitumor agents
7. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to national cancer institute treatment referral center 9103
8. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer
9. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer
10. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A gynecologic oncology group study
11. Taxol binds to polymerized tubulin in vitro
12. Taxol binds to cellular microtubules
13. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol
14. Demonstration of the cell cycle positions of Taxol-induced 'asters' and 'bundles' by sequential measurement of tubulin immunofluorescence, DNA content and autoradiographic labeling of Taxol-sensitive and -resistant cells
15. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations
16. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells
17. Divergent effects of Taxol on tumor necrosis factor-alpha-mediated cytolysis of ovarian carcinoma cells
18. Taxol increases steady-state levels of liposaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages
19. Phase II trial of Taxol in patients with metastatic renal cell carcinoma
20. Survival after phase II treatment of advanced renal cell carcinoma with Taxol or high-dose interleukin-2
21. Preclinical activity of Taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: Comparison with Taxol and conventional antineoplastic agents
22. Antiproliferative effects of paclitaxel (Taxol®) on human renal clear cell carcinomas in vitro
23. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas)
24. Cytogenetics of papillary renal cell tumors
25. Hereditary papillary renal cell carcinoma
26. Histological typing of kidney tumours
27. Mechanisms of multidrug resistance
28. MDR1 gene expression in lung cancer
29. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
30. Modulation of multidrug resistance: At the threshold
31. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene
32. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter in human multidrug resistant lung cancer cell lines
33. Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR-1 expression
34. Cytomorphological cytogenetic and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type
35. Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic and chromophobe cell variants of human renal cell carcinoma in vivo and in vitro
36. Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma
37. Chromophilic renal cell carcinoma: Cytomorphological and cytogenetic characterisation of four permanent cell lines
38. Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug resistant phenotype
39. Paclitaxel-induced cytotoxicity - The effects of cremophor EL (castor oil) on two human breast cancer cell lines acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein
40. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL
41. Cremophor EL solvent for paclitaxel and toxicity
42. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
43. The detection of rhodamine 123 efflux at low levels of drug resistance
44. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting the microtubule functions during anaphase and telophase
45. Taxol stabilizes microtubules in mouse fibroblast cells
46. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as chemosensitizer
47. New potent verapamil derivates that reverse multidrug resistance in human renal carcinoma cell and in transgenic mice expressing the human MDR1 gene
48. Cremophor EL enhances Taxol efficiacy in a multi-drug resistant C1300 neuroblastoma cell line
49. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs
50. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion of glutathione
51. Increase of β(III)- and β(IVa)-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance
52. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents